Late-onset periodic bradycardia during Vagus Nerve Stimulation in a pediatric patient. A new case and review of the literature
Abstract Background Epilepsy is a common diseases in the world. Around 10-40% of patients who suffer epilepsy will have intractable seizures. When resective epilepsy surgery is not possible, vagus nerve stimulation (VNS) can be an option. The most common side effects associated with VSN therapy are...
Saved in:
Published in | European journal of paediatric neurology Vol. 20; no. 4; pp. 678 - 683 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.07.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract Background Epilepsy is a common diseases in the world. Around 10-40% of patients who suffer epilepsy will have intractable seizures. When resective epilepsy surgery is not possible, vagus nerve stimulation (VNS) can be an option. The most common side effects associated with VSN therapy are hoarseness, throat pain and coughing. Cardiac arrhythmia has been reported during lead tests performed during implantation of the device, but few cases during regular treatment. We report a new child where vagally induced bradyarrhythmia, perfectly correlated with the stimulation periods. Clinical report 13 year-old girl with refractory mioclonic-astatic epilepsy since the age of two. When she was five years-old, a VNS was implanted with complete resolution of her seizures. But when she was 13, she began with sudden falls with loss of consciousness lasting less than 10 seconds, which were similar to her previous epileptic drop-attacks. Continuous ECG recording was normal but electrocardiography showed a bradycardia of 45 bpm with a syncope-like episode. It was necessary to turn off the VNS. Conclusions To our knowledge, there are just three paediatrics and four adults patients described in the literature with this severe and life-threatening side effect. Cardiac complications of VNS therapy are very infrequent but should alert clinicians to its possibility. A cardiac evaluation is mandatory before VNS implantation and periodically thereafter (probably between one or three years). |
---|---|
Bibliography: | ObjectType-Case Study-3 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Review-1 ObjectType-Feature-5 ObjectType-Report-2 ObjectType-Article-4 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 1090-3798 1532-2130 |
DOI: | 10.1016/j.ejpn.2016.02.014 |